Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.22
GSK's Cash-to-Debt is ranked lower than
81% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.05 vs. GSK: 0.22 )
Ranked among companies with meaningful Cash-to-Debt only.
GSK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.58 Max: N/A
Current: 0.22
Equity-to-Asset 0.01
GSK's Equity-to-Asset is ranked lower than
97% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. GSK: 0.01 )
Ranked among companies with meaningful Equity-to-Asset only.
GSK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0  Med: 0.25 Max: 0.67
Current: 0.01
0
0.67
Interest Coverage 5.15
GSK's Interest Coverage is ranked lower than
81% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.31 vs. GSK: 5.15 )
Ranked among companies with meaningful Interest Coverage only.
GSK' s Interest Coverage Range Over the Past 10 Years
Min: 3.71  Med: 9.74 Max: 17.51
Current: 5.15
3.71
17.51
Piotroski F-Score: 7
Altman Z-Score: 1.10
Beneish M-Score: -2.91
WACC vs ROIC
7.81%
14.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 12.48
GSK's Operating Margin % is ranked higher than
65% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.95 vs. GSK: 12.48 )
Ranked among companies with meaningful Operating Margin % only.
GSK' s Operating Margin % Range Over the Past 10 Years
Min: 9.32  Med: 27.93 Max: 43.15
Current: 12.48
9.32
43.15
Net Margin % 6.47
GSK's Net Margin % is ranked lower than
51% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. GSK: 6.47 )
Ranked among companies with meaningful Net Margin % only.
GSK' s Net Margin % Range Over the Past 10 Years
Min: 3.27  Med: 18.96 Max: 35.2
Current: 6.47
3.27
35.2
ROE % 221.39
GSK's ROE % is ranked higher than
99% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.91 vs. GSK: 221.39 )
Ranked among companies with meaningful ROE % only.
GSK' s ROE % Range Over the Past 10 Years
Min: 17.3  Med: 58.26 Max: 179.63
Current: 221.39
17.3
179.63
ROA % 3.30
GSK's ROA % is ranked lower than
54% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. GSK: 3.30 )
Ranked among companies with meaningful ROA % only.
GSK' s ROA % Range Over the Past 10 Years
Min: 1.62  Med: 12.76 Max: 18.45
Current: 3.3
1.62
18.45
ROC (Joel Greenblatt) % 35.25
GSK's ROC (Joel Greenblatt) % is ranked higher than
75% of the 793 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.48 vs. GSK: 35.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GSK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 25.79  Med: 83.7 Max: 120.14
Current: 35.25
25.79
120.14
3-Year Revenue Growth Rate 1.80
GSK's 3-Year Revenue Growth Rate is ranked lower than
62% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. GSK: 1.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GSK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.7  Med: 4.8 Max: 18.9
Current: 1.8
-7.7
18.9
3-Year EBITDA Growth Rate -20.50
GSK's 3-Year EBITDA Growth Rate is ranked lower than
89% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. GSK: -20.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GSK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.5  Med: 7.9 Max: 21.7
Current: -20.5
-20.5
21.7
3-Year EPS without NRI Growth Rate -44.80
GSK's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. GSK: -44.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GSK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.8  Med: 7.4 Max: 51.3
Current: -44.8
-44.8
51.3
GuruFocus has detected 3 Warning Signs with GlaxoSmithKline PLC $GSK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GSK's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

GSK Guru Trades in Q3 2016

John Hussman 50,000 sh (New)
Jeremy Grantham 1,563,336 sh (+909.39%)
Jim Simons 930,000 sh (+82.07%)
Kahn Brothers 632,040 sh (+66.18%)
NWQ Managers 2,658,155 sh (+28.09%)
Ken Fisher 11,861,172 sh (+1.11%)
First Eagle Investment 1 sh (unchged)
John Rogers 1,607,697 sh (unchged)
Murray Stahl 25,973 sh (unchged)
Francis Chou 18,000 sh (unchged)
Diamond Hill Capital 151,307 sh (unchged)
Pioneer Investments 542,025 sh (-0.20%)
PRIMECAP Management 1,109,085 sh (-0.62%)
Sarah Ketterer 327,419 sh (-0.72%)
Tweedy Browne 114,844 sh (-1.41%)
Joel Greenblatt 25,284 sh (-2.22%)
HOTCHKIS & WILEY 8,150,402 sh (-3.42%)
Jeff Auxier 105,772 sh (-4.48%)
Dodge & Cox 41,962 sh (-5.20%)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (-6.59%)
Charles Brandes 3,525,668 sh (-16.54%)
» More
Q4 2016

GSK Guru Trades in Q4 2016

John Paulson 296,000 sh (New)
Jim Simons 3,085,500 sh (+231.77%)
Kahn Brothers 833,315 sh (+31.85%)
Jeremy Grantham 1,820,174 sh (+16.43%)
Joel Greenblatt 26,315 sh (+4.08%)
John Rogers 1,646,146 sh (+2.39%)
Pioneer Investments 545,625 sh (+0.66%)
First Eagle Investment 1 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (unchged)
Francis Chou 18,000 sh (unchged)
Diamond Hill Capital 151,307 sh (unchged)
John Hussman Sold Out
Tweedy Browne 114,437 sh (-0.35%)
Ken Fisher 11,809,500 sh (-0.44%)
PRIMECAP Management 1,093,985 sh (-1.36%)
NWQ Managers 2,568,013 sh (-3.39%)
HOTCHKIS & WILEY 7,807,200 sh (-4.21%)
Murray Stahl 23,973 sh (-7.70%)
Sarah Ketterer 294,560 sh (-10.04%)
Charles Brandes 3,149,621 sh (-10.67%)
Dodge & Cox 36,762 sh (-12.39%)
Jeff Auxier 89,247 sh (-15.62%)
» More
Q1 2017

GSK Guru Trades in Q1 2017

Jim Simons 4,402,100 sh (+42.67%)
John Paulson 415,100 sh (+40.24%)
Kahn Brothers 1,050,995 sh (+26.12%)
Diamond Hill Capital 190,052 sh (+25.61%)
Sarah Ketterer 315,515 sh (+7.11%)
Charles Brandes 3,363,788 sh (+6.80%)
Ken Fisher 11,969,866 sh (+1.36%)
Murray Stahl 24,073 sh (+0.42%)
NWQ Managers 2,568,415 sh (+0.02%)
First Eagle Investment 1 sh (unchged)
John Rogers 1,646,146 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (unchged)
PRIMECAP Management 1,093,985 sh (unchged)
Francis Chou Sold Out
Pioneer Investments 541,525 sh (-0.75%)
Jeff Auxier 88,147 sh (-1.23%)
Tweedy Browne 110,579 sh (-3.37%)
Joel Greenblatt 25,392 sh (-3.51%)
HOTCHKIS & WILEY 7,524,627 sh (-3.62%)
Dodge & Cox 32,187 sh (-12.44%)
Jeremy Grantham 610,400 sh (-66.46%)
» More
Q2 2017

GSK Guru Trades in Q2 2017

Steven Cohen 100,000 sh (New)
Jim Simons 9,338,000 sh (+112.13%)
Sarah Ketterer 425,047 sh (+34.72%)
Pioneer Investments 623,997 sh (+15.23%)
Ken Fisher 12,534,385 sh (+4.72%)
Joel Greenblatt 26,495 sh (+4.34%)
HOTCHKIS & WILEY 7,847,327 sh (+4.29%)
Kahn Brothers 1,055,085 sh (+0.39%)
Diamond Hill Capital 190,052 sh (unchged)
First Eagle Investment 1 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (unchged)
John Rogers 1,646,146 sh (unchged)
Murray Stahl 24,073 sh (unchged)
Charles Brandes 3,361,346 sh (-0.07%)
Tweedy Browne 109,584 sh (-0.90%)
Jeff Auxier 86,909 sh (-1.40%)
PRIMECAP Management 1,075,535 sh (-1.69%)
NWQ Managers 2,494,769 sh (-2.87%)
Dodge & Cox 29,687 sh (-7.77%)
John Paulson 289,500 sh (-30.26%)
Jeremy Grantham 304,800 sh (-50.07%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:GSK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Add 4.72%0.04%$40.68 - $44.37 $ 38.75-9%12,534,385
HOTCHKIS & WILEY 2017-06-30 Add 4.29%0.06%$40.68 - $44.37 $ 38.75-9%7,847,327
Charles Brandes 2017-06-30 Reduce -0.07%$40.68 - $44.37 $ 38.75-9%3,361,346
NWQ Managers 2017-06-30 Reduce -2.87%0.04%$40.68 - $44.37 $ 38.75-9%2,494,769
Kahn Brothers 2017-06-30 Add 0.39%0.03%$40.68 - $44.37 $ 38.75-9%1,055,085
John Paulson 2017-06-30 Reduce -30.26%0.07%$40.68 - $44.37 $ 38.75-9%289,500
Tweedy Browne 2017-06-30 Reduce -0.90%$40.68 - $44.37 $ 38.75-9%109,584
Dodge & Cox 2017-06-30 Reduce -7.77%$40.68 - $44.37 $ 38.75-9%29,687
Joel Greenblatt 2017-06-30 Add 4.34%$40.68 - $44.37 $ 38.75-9%26,495
Ken Fisher 2017-03-31 Add 1.36%0.01%$38.72 - $42.73 $ 38.75-5%11,969,866
HOTCHKIS & WILEY 2017-03-31 Reduce -3.62%0.04%$38.72 - $42.73 $ 38.75-5%7,524,627
Charles Brandes 2017-03-31 Add 6.80%0.13%$38.72 - $42.73 $ 38.75-5%3,363,788
NWQ Managers 2017-03-31 Add 0.02%$38.72 - $42.73 $ 38.75-5%2,568,415
Kahn Brothers 2017-03-31 Add 26.12%1.58%$38.72 - $42.73 $ 38.75-5%1,050,995
John Paulson 2017-03-31 Add 40.24%0.07%$38.72 - $42.73 $ 38.75-5%415,100
Tweedy Browne 2017-03-31 Reduce -3.37%$38.72 - $42.73 $ 38.75-5%110,579
Dodge & Cox 2017-03-31 Reduce -12.44%$38.72 - $42.73 $ 38.75-5%32,187
Joel Greenblatt 2017-03-31 Reduce -3.51%$38.72 - $42.73 $ 38.75-5%25,392
Ken Fisher 2016-12-31 Reduce -0.44%$37.39 - $43.44 $ 38.75-2%11,809,500
HOTCHKIS & WILEY 2016-12-31 Reduce -4.21%0.06%$37.39 - $43.44 $ 38.75-2%7,807,200
Charles Brandes 2016-12-31 Reduce -10.67%0.24%$37.39 - $43.44 $ 38.75-2%3,149,621
NWQ Managers 2016-12-31 Reduce -3.39%0.06%$37.39 - $43.44 $ 38.75-2%2,568,013
John Rogers 2016-12-31 Add 2.39%0.02%$37.39 - $43.44 $ 38.75-2%1,646,146
Kahn Brothers 2016-12-31 Add 31.85%1.31%$37.39 - $43.44 $ 38.75-2%833,315
John Paulson 2016-12-31 New Buy0.15%$37.39 - $43.44 $ 38.75-2%296,000
Tweedy Browne 2016-12-31 Reduce -0.35%$37.39 - $43.44 $ 38.75-2%114,437
Dodge & Cox 2016-12-31 Reduce -12.39%$37.39 - $43.44 $ 38.75-2%36,762
Joel Greenblatt 2016-12-31 Add 4.08%$37.39 - $43.44 $ 38.75-2%26,315
Ken Fisher 2016-09-30 Add 1.11%0.01%$42.5 - $45.49 $ 38.75-12%11,861,172
HOTCHKIS & WILEY 2016-09-30 Reduce -3.42%0.05%$42.5 - $45.49 $ 38.75-12%8,150,402
Charles Brandes 2016-09-30 Reduce -16.54%0.46%$42.5 - $45.49 $ 38.75-12%3,525,668
NWQ Managers 2016-09-30 Add 28.09%0.37%$42.5 - $45.49 $ 38.75-12%2,658,155
Kahn Brothers 2016-09-30 Add 66.18%1.98%$42.5 - $45.49 $ 38.75-12%632,040
Barrow, Hanley, Mewhinney & Strauss 2016-09-30 Reduce -6.59%$42.5 - $45.49 $ 38.75-12%235,200
Tweedy Browne 2016-09-30 Reduce -1.41%$42.5 - $45.49 $ 38.75-12%114,844
Dodge & Cox 2016-09-30 Reduce -5.20%$42.5 - $45.49 $ 38.75-12%41,962
Joel Greenblatt 2016-09-30 Reduce -2.22%$42.5 - $45.49 $ 38.75-12%25,284
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:LSE:AZN, OTCPK:GWPRF, LSE:DPH, LSE:VEC, LSE:EAH, LSE:AGY, LSE:FUM, LSE:SAR, LSE:N4P » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, GSK.Switzerland, GSK.UK, GLAXF.USA,
Headquarter Location:UK
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related consumer products.

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across multiple therapeutic classes, including respiratory and antiviral, as well as vaccines and healthcare-related consumer products.

Guru Investment Theses on GlaxoSmithKline PLC

Ariel Funds Comments on GlaxoSmithKline plc - Sep 28, 2016

In addition, GlaxoSmithKline plc (NYSE:GSK) rallied +7.74%1 in the second quarter, after reporting profit growth for the first time since 2013. Glaxo is seeing benefits from its purchase of Novartis’ vaccines unit. Demand for vaccines and new drugs helped offset declines in the sales of blockbuster asthma medication Advair.

From John Rogers (Trades, Portfolio)' second quarter 2016 Ariel Global Fund commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about GlaxoSmithKline PLC

Stocks That Fell to 3-Year Lows in the Week of August 11 GlaxoSmithKline PLC (GSK), Simon Property Group Inc (SPG), GGP Inc (GGP), and CenturyLink Inc (CTL) have declined to their respective three-year lows.
GlaxoSmithKline PLC (NYSE:GSK), Simon Property Group Inc (NYSE:SPG), GGP Inc (NYSE:GGP), and CenturyLink Inc (NYSE:CTL) have declined to their three-year lows. Read more...
GSK ships 2017-18 seasonal influenza vaccines for US market
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting
Kahn Brothers Buys BlackBerry, Novartis, Assured Guaranty Guru's largest 1st-quarter purchases
Irving Kahn, along with brothers Alan and Thomas, founded Kahn Brothers (Trades, Portfolio) in 1978. During the first quarter the guru bought shares in the following stocks: Read more...
Pernix: An Investor's Rationale to Staying Long The stock has fallen a bit, but there's a good reason investors are staying long
I am letting you know from the beginning, I am long Pernix Therapeutics Holdings Inc. (NASDAQ:PTX). While I may have gotten to the point where I play hide-and-seek with the daily share price fluctuations, I am far from throwing in the towel on this company. I am not stubborn to the point of becoming poor, nor do I enjoy frequent episodes of pain. Rather, I tend to have the ability to cut through the minutiae and get to the nitty gritty of the issue at hand. As such, despite Pernix's current issues, I still see significant upside value. Read more...
Jeff Auxier Reduces, Exits Multiple Positions in 4th Quarter Guru releases quarterly portfolio
Jeff Auxier (Trades, Portfolio) is the founder of Auxier Asset Management. His portfolio consists of 152 stocks with a total value of $460 million. During the fourth quarter of 2016, the guru sold shares in the following stocks: Read more...
Gilead Sciences Must Answer to Investors After a Disappointing 2016 Investors are concerned about the company's lack of a plan for the future
Gilead Sciences Inc. (NASDAQ:GILD) delivered a poor performance last year. The stock lost over 24% in 2016, caused by a drop in sales of products that treat hepatitis C. According to Ben Levinsohn in a Barron's article, the decline was also attributed to the company’s lack of a plan for the future. Read more...
GlaxoSmithKline, Vodafone Hit 3-Year Low Prices 4 stocks that present opportunities to buy
GlaxoSmithKline PLC (NYSE:GSK), Diageo PLC (NYSE:DEO), Vodafone Group PLC (NASDAQ:VOD) and National Grid PLC (NYSE:NGG) have reached their three-year low prices. Read more...
Jeff Auxier Curbs Multiple Positions in 3rd Quarter Guru releases quarterly portfolio
Jeff Auxier (Trades, Portfolio) manages the  Auxier Focus Fund.The guru made the following reductions during the third quarter: Read more...
Kahn Brothers Adds to 4 Holdings in 3rd Quarter Largest acquisition is in GlaxoSmithKline
Kahn Brothers (Trades, Portfolio) added to four holdings in its portfolio in the third quarter. Read more...

Ratios

vs
industry
vs
history
PE Ratio 38.21
GSK's PE Ratio is ranked lower than
76% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.93 vs. GSK: 38.21 )
Ranked among companies with meaningful PE Ratio only.
GSK' s PE Ratio Range Over the Past 10 Years
Min: 6.35  Med: 14.71 Max: 99999999.99
Current: 38.21
6.35
99999999.99
Forward PE Ratio 13.50
GSK's Forward PE Ratio is ranked higher than
70% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.90 vs. GSK: 13.50 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 38.21
GSK's PE Ratio without NRI is ranked lower than
76% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.21 vs. GSK: 38.21 )
Ranked among companies with meaningful PE Ratio without NRI only.
GSK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.38  Med: 14.65 Max: 284.83
Current: 38.21
6.38
284.83
Price-to-Owner-Earnings 12.51
GSK's Price-to-Owner-Earnings is ranked higher than
80% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.90 vs. GSK: 12.51 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GSK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.81  Med: 15.09 Max: 125.21
Current: 12.51
4.81
125.21
PB Ratio 90.30
GSK's PB Ratio is ranked lower than
98% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. GSK: 90.30 )
Ranked among companies with meaningful PB Ratio only.
GSK' s PB Ratio Range Over the Past 10 Years
Min: 5.48  Med: 9.41 Max: 610.36
Current: 90.3
5.48
610.36
PS Ratio 2.46
GSK's PS Ratio is ranked higher than
52% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. GSK: 2.46 )
Ranked among companies with meaningful PS Ratio only.
GSK' s PS Ratio Range Over the Past 10 Years
Min: 1.94  Med: 2.77 Max: 3.68
Current: 2.46
1.94
3.68
Price-to-Free-Cash-Flow 15.88
GSK's Price-to-Free-Cash-Flow is ranked higher than
69% of the 208 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. GSK: 15.88 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GSK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.24  Med: 16.56 Max: 136.91
Current: 15.88
8.24
136.91
Price-to-Operating-Cash-Flow 10.63
GSK's Price-to-Operating-Cash-Flow is ranked higher than
75% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.02 vs. GSK: 10.63 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GSK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.62  Med: 11.73 Max: 27.46
Current: 10.63
6.62
27.46
EV-to-EBIT 24.18
GSK's EV-to-EBIT is ranked lower than
65% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. GSK: 24.18 )
Ranked among companies with meaningful EV-to-EBIT only.
GSK' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 10.7 Max: 72.6
Current: 24.18
6.3
72.6
EV-to-EBITDA 15.23
GSK's EV-to-EBITDA is ranked lower than
56% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.50 vs. GSK: 15.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
GSK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 9.2 Max: 35.2
Current: 15.23
5.6
35.2
Shiller PE Ratio 16.38
GSK's Shiller PE Ratio is ranked higher than
84% of the 198 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.37 vs. GSK: 16.38 )
Ranked among companies with meaningful Shiller PE Ratio only.
GSK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.71  Med: 15.15 Max: 20
Current: 16.38
11.71
20
Current Ratio 0.57
GSK's Current Ratio is ranked lower than
92% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. GSK: 0.57 )
Ranked among companies with meaningful Current Ratio only.
GSK' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.29 Max: 2.64
Current: 0.57
0.57
2.64
Quick Ratio 0.37
GSK's Quick Ratio is ranked lower than
91% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.82 vs. GSK: 0.37 )
Ranked among companies with meaningful Quick Ratio only.
GSK' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1 Max: 2.24
Current: 0.37
0.37
2.24
Days Inventory 194.83
GSK's Days Inventory is ranked lower than
82% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. GSK: 194.83 )
Ranked among companies with meaningful Days Inventory only.
GSK' s Days Inventory Range Over the Past 10 Years
Min: 167.28  Med: 188.56 Max: 202.64
Current: 194.83
167.28
202.64
Days Sales Outstanding 78.21
GSK's Days Sales Outstanding is ranked lower than
56% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. GSK: 78.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
GSK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 59.8 Max: 93.9
Current: 78.21
54.62
93.9

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 5.22
GSK's Dividend Yield % is ranked higher than
96% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. GSK: 5.22 )
Ranked among companies with meaningful Dividend Yield % only.
GSK' s Dividend Yield % Range Over the Past 10 Years
Min: 3.09  Med: 5.14 Max: 6.24
Current: 5.22
3.09
6.24
Dividend Payout Ratio 2.00
GSK's Dividend Payout Ratio is ranked lower than
97% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. GSK: 2.00 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GSK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.46  Med: 0.75 Max: 4.3
Current: 2
0.46
4.3
3-Year Dividend Growth Rate -1.30
GSK's 3-Year Dividend Growth Rate is ranked lower than
66% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. GSK: -1.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
GSK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5 Max: 62.4
Current: -1.3
0
62.4
Forward Dividend Yield % 5.12
GSK's Forward Dividend Yield % is ranked higher than
95% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. GSK: 5.12 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.42
GSK's 5-Year Yield-on-Cost % is ranked higher than
86% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. GSK: 5.42 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GSK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.22  Med: 5.35 Max: 6.49
Current: 5.42
3.22
6.49
3-Year Average Share Buyback Ratio -0.30
GSK's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 473 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. GSK: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GSK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.7  Med: -0.5 Max: 4.7
Current: -0.3
-26.7
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.15
GSK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
51% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. GSK: 2.15 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GSK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.96  Med: 1.97 Max: 70.18
Current: 2.15
0.96
70.18
Price-to-Median-PS-Value 0.88
GSK's Price-to-Median-PS-Value is ranked higher than
60% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. GSK: 0.88 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GSK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.62  Med: 1.18 Max: 3.37
Current: 0.88
0.62
3.37
Earnings Yield (Greenblatt) % 4.14
GSK's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. GSK: 4.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GSK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.4  Med: 9.3 Max: 15.8
Current: 4.14
1.4
15.8
Forward Rate of Return (Yacktman) % -8.54
GSK's Forward Rate of Return (Yacktman) % is ranked lower than
84% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. GSK: -8.54 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GSK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -9.1  Med: 8.6 Max: 17.4
Current: -8.54
-9.1
17.4

More Statistics

Revenue (TTM) (Mil) $37,869.95
EPS (TTM) $ 0.99
Beta0.98
Short Percentage of Float0.00%
52-Week Range $37.20 - 44.58
Shares Outstanding (Mil)2,459.00 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 38,482 39,280 38,524
EPS ($) 2.87 2.80 2.88
EPS without NRI ($) 2.87 2.80 2.88
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.49%
Dividends per Share ($) 2.09 2.09 2.09
» More Articles for GSK

Headlines

Articles On GuruFocus.com
Stocks That Fell to 3-Year Lows in the Week of August 11 Aug 13 2017 
What Financial Modeling Says About Gilead Sciences Jul 26 2017 
GSK ships 2017-18 seasonal influenza vaccines for US market Jul 14 2017 
Vaccine Small-Cap Just Took a Big Step Forward Jun 26 2017 
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine S Jun 21 2017 
VBI Vaccines Just Took a Major Step Forward in Its HBV Program Jun 21 2017 
DarioHealth: Disruption Is Valuable Jun 07 2017 
Kahn Brothers Buys BlackBerry, Novartis, Assured Guaranty May 31 2017 
Seth Klarman Backs Out of Innoviva Days After Activist Stakeholder Defeated May 10 2017 
Pernix: An Investor's Rationale to Staying Long Mar 23 2017 

More From Other Websites
Mylan Finalizes Settlement Agreement with DOJ for $465M Aug 18 2017
[$$] The questionable strategy of a pharmaceuticals CEO Aug 17 2017
Shire Gains as it Seeks European Approval For Dry Eye Treatment Aug 15 2017
[$$] The key to innovation is balancing risk and rigour Aug 14 2017
What Happened In Biotech Last Week? Aug 14 2017
Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up Aug 14 2017
Stocks That Fell to 3-Year Lows in the Week of August 11 Aug 13 2017
Where Does Zika Virus Vaccine Research Stand Now? Aug 12 2017
ETFs with exposure to GlaxoSmithKline Plc : August 11, 2017 Aug 11 2017
Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some... Aug 11 2017
Biotech movers: Ionis Drops After GSK Bows Out of Partnership Aug 11 2017
Former GSK exec resigns from Intellia board due to 'conflict' Aug 10 2017
UK fraud office expects decision on GSK, Rolls-Royce cases next year Aug 10 2017
3 High-Yield Healthcare Stocks Aug 10 2017
European Stocks Set for Mixed Open as Global Markets Stabilize Aug 10 2017
[$$] Blockbuster drugs depend on marketing, not design Aug 09 2017
Mexico watchdog finds big pharma faces no competition on some drugs Aug 09 2017
Drugmakers' hopes for gene therapy rise despite tiny sales in Europe Aug 08 2017
Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2 Aug 07 2017
[$$] GSK chief vows to stop 'drifting off in hobbyland' with R&D Aug 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}